事关政府投资基金，四部门重磅发文。 1月12日，国家发展改革委等四部门联合印发《关于加强政府投资基金布局规划和投向指导的工作办法(试行)》（以下简称《工作办法》）。同时，国家 发展改革委也同步出台了《政府投资基金投向评价管理办法（试行）》（以下简称《管理办法》）的通知。 其中提到，主要考察基金投向是否符合支持新质生产力发展，支持的投向领域包括：培育新兴产业、未来产业。新兴产业主要包括新一代信息技术、新能 源、新材料、高端装备、新能源汽车、绿色环保、民用航空和船舶与海洋工程装备等领域；未来产业主要包括元宇宙、脑机接口、量子信息、人形机器 人、生成式人工智能、生物制造、生物育种、未来显示、未来网络、新型储能等领域。 四部门重磅发布 1月12日，国家发展改革委、财政部、科技部、工业和信息化部联合发布《关于加强政府投资基金布局规划和投向指导的工作办法》（以下简称《工作办 法》）。国家发展改革委相关负责人表示，这是首次在国家层面对政府投资基金的布局和投向作出系统规范。 据央视新闻，《工作办法》围绕政府投资基金"投向哪、怎么投、谁来管"三方面，提出14项政策举措。 在优化基金布局方面，要求基金支持重大战略、重点领域和市场 ...

Investment Rating - The investment rating for the industry is "Positive" and the rating has been maintained [1] Core Insights - The pharmaceutical and biotechnology industry index increased by 5.60%, ranking 8th among 31 primary industries, outperforming the CSI 300 index which rose by 2.18% [4][16] - The PE (TTM overall method, excluding negative values) for the pharmaceutical and biotechnology industry as of January 9, 2026, is 30.56x, up from 29.20x at the end of the previous period, indicating an upward valuation trend [4][21] - The top three sub-industries in terms of PE are vaccines (47.64x), hospitals (43.33x), and medical devices (39.44x), while pharmaceutical circulation has the lowest valuation at 15.42x [4][21] Industry Review - The report highlights significant developments in the pharmaceutical sector, including the release of the "Fourth Batch of Encouraged Generic Drug Catalog" aimed at optimizing the drug supply guarantee system and enhancing industry structure [6][26] - The report notes that 43 listed companies in the pharmaceutical and biotechnology sector experienced a net reduction in shareholder holdings amounting to 2.779 billion yuan, with 8 companies increasing holdings by 20 million yuan and 35 companies reducing holdings by 2.799 billion yuan [4] Important Industry News - The National Health Commission and other departments released the "Fourth Batch of Encouraged Generic Drug Catalog," which includes 21 varieties and 47 specifications, focusing on clinical needs and disease burdens [26][27] - The NMPA announced measures to strengthen the supervision and management of entrusted drug production, aiming to enhance drug quality assurance levels [29][30] - The NMPA also optimized the review and approval process for urgently needed overseas drugs, encouraging simultaneous global development and submission [31][32] Investment Recommendations - The report suggests focusing on innovative pharmaceutical companies with strong pipeline differentiation, rapid clinical advancement, and robust overseas collaboration capabilities [7][8] - In the medical device sector, it recommends paying attention to companies with solid technical foundations and deep collaborations with leading hospitals and research institutions [8]

A股走到今天，我们应该要明白一点，那就是股市已经往大牛市的预期去走了，夸张点甚至可以说是有点像15年大牛市，今天两市成交额为3.64万亿，突破 此前"924行情"创下的3.49万亿最高纪录，要知道今天证券、"易中天"、新能源等权重股都没怎么表现，纯粹是商业航天、AI应用等题材堆出来的；然后今 天上证指数续写17连阳记录；最后周末的20万颗卫星，这个消息周五就有了，周末高度发酵，按以往来说涨这多后资金肯定会借机出货，但今天商业航天依 然暴涨。 种种迹象表示A股做多热情彻底被点燃了。 周末大家应该有看到这张图，今天这么一暴涨，估计晚上又要发酵了，这会不会进一步强化大水牛的预期？ 周末中信证券的策略写的比较好： 很多机构去年年度减仓了、准备等开年大盘调整再上车，但谁知道年初增量资金强劲指数继续连阳，这里机构就慌了被迫追回来了，另外去年的赚钱效应、 和年初指数的连阳强势信号，又吸引了更多的资金进场。 周末的文章有跟大家提过，除了商业航天外，AI应用是最热门的板块，特别是geo概念。我在周五的文章特地写过：机构认为互联网流量红利已完成三 次关键迭代:2000年起搜索流量时代催生SEO、淘宝客机遇;随后推荐流量时代成就短 ...

Core Viewpoint - A-shares have witnessed a historic surge, with trading volumes reaching unprecedented levels, indicating strong market momentum and investor confidence in various sectors, particularly in commercial aerospace and AI applications [1][3]. Group 1: Market Performance - On January 12, the Shanghai Composite Index broke through 4150 points, with trading volumes exceeding 3.6 trillion yuan, marking a significant increase of 478.7 billion yuan from the previous trading day [1]. - The trading volume surpassed 2 trillion yuan for the second consecutive day and exceeded 3 trillion yuan for the first time since October 8, 2024 [1]. Group 2: Leverage and Fund Inflows - In the first week of January, net inflows of leveraged funds reached 85.779 billion yuan, ranking fifth in A-share history for weekly inflows [3]. - The margin trading balance hit a record high of 26,276.01 billion yuan, accounting for 2.55% of the A-share market's circulating market value [3][5]. Group 3: Sector Analysis - All sectors except utilities and food and beverage saw significant net inflows of leveraged funds, with the electronics sector leading at 15.812 billion yuan, followed by non-ferrous metals at 9.562 billion yuan, and defense and military at 9.173 billion yuan [5]. - The number of margin trading accounts reached a decade-high, with 1.5421 million new accounts opened in 2025, reflecting a 52% increase from 2024 [5]. Group 4: Future Market Outlook - According to CITIC Securities, the current market excitement is driven by pent-up demand from investors, with expectations of continued momentum in thematic sectors until the National People's Congress [6]. - Huatai Securities suggests that while the spring market may still have room for growth, the concentration of trading structures indicates a potential shift towards rotation among hot sectors [6][7]. - The potential new marginal drivers for A-shares include abnormal inflows into A500 ETF, the appreciation of the yuan reflecting international confidence, and active themes such as AI and commercial aerospace [7].

Core Insights - The brain-computer interface (BCI) market is gaining significant attention following Elon Musk's announcement of large-scale production plans for his company Neuralink starting in 2026, shifting perceptions from skepticism to optimism about commercialization [1] - Current applications of BCI technology are still in clinical trial phases, facing ethical and social acceptance challenges, leading to varied growth forecasts from different institutions [1] - Grand View Research reports that the BCI market size grew from $1.2 billion in 2019 to nearly $2 billion in 2023, with a compound annual growth rate (CAGR) exceeding 13%, and is expected to reach $7.63 billion by 2029 with a CAGR of 25.2% from 2024 to 2029 [1] Market Overview - The domestic BCI industry in China has advanced from a "follower" to a "co-runner and partial leader" position globally, with the market size increasing from approximately 1 billion RMB in 2020 to about 1.73 billion RMB in 2023, capturing 12.5% of the global market [3][5] - The CAGR for China's BCI market is reported at 20%, significantly higher than the global average of 14% [3] Drivers of Growth - Policy support includes the inclusion of brain science in China's 14th Five-Year Plan and local subsidies reaching up to 30 million RMB, alongside the development of national standards for BCI expected by 2025 [5] - Capital investment in the domestic BCI sector exceeded 6.5 billion RMB from 2021 to 2023, accounting for 28% of global financing, with notable single-round financing records [5] - Technological advancements include breakthroughs in electrode channel counts by Chinese universities and significant reductions in power consumption and costs for non-invasive BCI technologies [6] Application and Market Segmentation - Medical rehabilitation remains the largest segment, accounting for approximately 65% of the current market, with the average price of domestic "brain-controlled robotic arms" decreasing from 1.2 million RMB in 2019 to 450,000 RMB in 2023 [6] - Consumer applications in education, entertainment, and industrial safety are emerging, with the consumer segment's market share increasing to 18% in 2023 and expected to exceed 30% by 2026 [6] Future Projections - The Chinese BCI market is projected to reach approximately 5 billion RMB by 2026 and aim for 20 billion RMB by 2030, potentially capturing 25% of the global market [7] - China is expected to not only expand its market but also to set standards and solutions, positioning itself as a "second pole" in the global BCI industry [7] Investment Opportunities - The BCI sector's complexity suggests that investing in ETFs could be a strategic approach to capture the full spectrum of opportunities across the value chain, including software algorithms and medical technology [8] - The software segment, which translates neural signals into machine language, is critical for BCI commercialization, with 15% of the CSI Software Service Index now associated with BCI [8] - The medical technology segment is highlighted as the most immediate commercial application for BCI, with significant representation in the CSI Medical Device Index, which includes leading companies in the field [11]

Core Viewpoint - The company, Invt (002334.SZ), has confirmed that its human-machine interface (HMI) products are widely used across various industries, including textiles, packaging, water treatment, woodworking, healthcare, food, and agriculture. However, the company currently does not have any applications related to brain-machine interfaces [1]. Group 1 - The company’s human-machine interface products are utilized in multiple sectors such as textiles, packaging, water treatment, woodworking, healthcare, food, and agriculture [1]. - There is no current research or business development in brain-machine interface technology by the company [1].

Group 1: AI Applications and Brain-Computer Interface (BCI) Sector - The AI application sector is leading the market, with significant gains observed in stocks such as Zhiyu, Weimeng Group, and Kingsoft Cloud [2] - The brain-computer interface sector is experiencing a strong performance, driven by positive news from the Tianjin University BCI laboratory focusing on non-invasive BCI technology [2][3] - The Tianjin University BCI laboratory has developed a comprehensive chain from high-performance devices to clinical applications, including products for stroke rehabilitation and emotional state detection in astronauts [6] Group 2: Commercial Aerospace Sector - The commercial aerospace sector continues to show strong activity, with related stocks performing well [7] - Recent government initiatives in Zhejiang and Shanghai are aimed at promoting low-orbit satellite internet and advanced manufacturing in the aerospace sector [10] Group 3: Stock Performance Highlights - Notable stock performances in the BCI sector include: - Yinkang Life: +12.16% [5] - Beiyikang: +11.89% [5] - Aipeng Medical: +10.94% [5] - Hai Ge Communication: +10.00% [5] - The commercial aerospace sector also saw significant gains, with stocks like Tianli Composite up by 24.96% and Zhongtai Co. up by 20.02% [8]

Core Viewpoint - Shanghai Lingang (600848.SH) has invested in Shanghai Lingang Sinan Life Technology Co., Ltd., acquiring a 20% stake through its wholly-owned subsidiary, Shanghai Lingang Pujiang International Technology City Development Co., Ltd. [1] Group 1: Investment Details - The investment involves Shanghai Lingang Sinan Life Technology Co., Ltd., which operates the Sinan Life Technology Super Incubator and the Sinan Brain-Machine Intelligence Super Incubator [1] - The Sinan Brain-Machine Intelligence Super Incubator is a key innovation component of the future industrial cluster for brain-machine interfaces in Shanghai [1] Group 2: Operational Focus - The incubator focuses on brain science and brain-machine interface fields, providing specialized concept validation services and enterprise incubation acceleration services based on cutting-edge technology [1] - Shanghai Lingang Sinan Life Technology Co., Ltd. aims to establish a technology collaborative innovation system that spans the entire chain from "data-algorithm-hardware-system" [1] Group 3: Research and Development Goals - The company will develop solutions for precise perception, intervention, treatment, and rehabilitation of brain activity [1]

Group 1 - A total of 27 companies received attention from well-known institutions in the past week [1] - Notable companies include Chengdu Xian Dao and Shangji Technology, which are expected to launch products by March 2026 [1] - Various investment firms such as Gao Yi Asset and Chengdu Xian Dao are involved in the analysis of these companies [3][4] Group 2 - Companies like Dongfang Shenghong and Weichai Power are also highlighted in the recent institutional focus [5] - The list of companies includes notable names such as BOE Technology Group and Jiangnan Chemical [5]

Investment Rating - The report rates the electronic industry as "Outperform" compared to the market [1]. Core Insights - Neuralink is set to begin large-scale production of brain-computer interface (BCI) devices in 2026, transitioning to a more streamlined and nearly fully automated surgical process [2][5]. - The global BCI market is projected to reach $3.3 billion by 2026, with a compound annual growth rate (CAGR) of 12.7% from 2024 to 2026 [15][16]. - Non-invasive BCI technology is expected to dominate the market, accounting for over 80% of the BCI products by 2024 [16]. Summary by Sections Neuralink Development History - Neuralink was founded in 2016 by Elon Musk, focusing on invasive brain-computer interfaces and AI integration into the human cortex [6]. - The first product was launched in 2019, featuring ultra-thin flexible electrodes and a custom microchip [9]. Overview of Brain-Computer Interfaces - BCIs establish a direct communication pathway between the brain and external devices, aiming to interpret brain activity and convert it into commands for controlling devices [10]. Market Analysis - The global BCI market is expected to reach $2.6 billion in 2024, with a year-on-year growth of 8.3% [15]. - In China, the BCI market is projected to reach $460 million in 2024, growing by 18.5% [15]. Non-Invasive BCI Manufacturers - Companies like Kernel, Neurable, and MindMaze are actively developing non-invasive BCI technologies [20]. - Domestic companies such as Strong Brain Technology and Xiangyu Medical are also making significant advancements in this field [20].